Early mannitol administration improves clinical outcomes of pediatric patients with brain edema

  • Putu A. Sekarningrum Department of Pediatric, Faculty of Medicine, University of Udayana/Sanglah Hospital, Bali
  • Dyah K. Wati Department of Pediatric, Faculty of Medicine, University of Udayana/Sanglah Hospital, Bali
  • IGN Made Suwarba Department of Pediatric, Faculty of Medicine, University of Udayana/Sanglah Hospital, Bali
  • I Nyoman B. Hartawan Department of Pediatric, Faculty of Medicine, University of Udayana/Sanglah Hospital, Bali
  • Dewi S. Mahalini Department of Pediatric, Faculty of Medicine, University of Udayana/Sanglah Hospital, Bali
  • IB Gede Suparyatha Department of Pediatric, Faculty of Medicine, University of Udayana/Sanglah Hospital, Bali
Keywords: brain edema, clinical outcome, intracranial pressure, mannitol
Abstract viewed: 1640 times
PDF downloaded: 892 times
HTML downloaded: 953 times
EPUB downloaded: 195 times

Abstract

Background: Mannitol 20% is used to treat patients with decreased consciousness and as the first line of treatment to reduce intracranial pressure (ICP). However, its application in pediatric patients is still based on minimal evidence. This study was performed to determine the predictive factors of clinical outcomes in pediatric patients with brain edema in the pediatric intensive care unit (PICU).

Methods: This prospective cohort study was conducted in the PICU, Sanglah Hospital Denpasar, Bali, Indonesia. The subjects were chosen by consecutive sampling from July 2016 to July 2017. The primary outcome variable was the patient’s clinical outcome. A chi-square test was used to evaluate the association between the timing of mannitol administration and the patient's clinical outcome. Multivariate analysis was performed on all variables with p≤0.25.

Results: Forty-one patients were included in the study, 65% of them were male, 65% had good nutritional status, 90% had non-traumatic brain injury, and 73% had confirmed intracranial infection. The risk of sequelae or death for patients in a coma was 1.8 times greater than that of non-comatose patients (p=0.018; CI 95% 1.119–3.047). Based on the timing of mannitol administration from the onset of decreased consciousness, the risk of sequelae or death in patients who received mannitol after 24 hours was 2.1 times higher than that in patients who received mannitol within 24 hours (p=0.006; CI 95% 1.167–3.779). Based on multivariate analysis, only two variables were associated with the patient’s clinical outcome: pediatric Glasgow coma scale (PGCS) ≤3 (p=0.03) and timing of mannitol administration >24 hours (p=0.01).

Conclusion: Early administration (<24 hours) of mannitol and high PGCS are related to favorable outcomes in patients with brain edema in the PICU.

Author Biographies

Putu A. Sekarningrum, Department of Pediatric, Faculty of Medicine, University of Udayana/Sanglah Hospital, Bali
pediatric resident
Dyah K. Wati, Department of Pediatric, Faculty of Medicine, University of Udayana/Sanglah Hospital, Bali
pediatric consultant ERIA

References

  1. Gwer S, Gatakaa H, Mwai L, Idro R, Newton CR. The role of osmotic agents in children with acute encephalopathies: a systematic review. BMC Pediatr. 2010;10:23. https://doi.org/10.1186/1471-2431-10-23

  2. Oertel M, Kelly DF, Lee JH, McArthur DL, Glenn TC, Vespa P, et al. Efficacy of hyperventilation, blood pressure elevation, and metabolic suppression therapy in controlling intracranial pressure after head injury. J Neurosurg. 2002;97(5):1045–53. https://doi.org/10.3171/jns.2002.97.5.1045

  3. Nara I, Shiogai T, Hara M, Saito I. Comparative effects of hypothermia, barbiturate, and osmotherapy for cerebral oxygen metabolism, intracranial pressure, and cerebral perfusion pressure in patients with severe head injury. Acta Neurochir Suppl. 1998;71:22–6. https://doi.org/10.1007/978-3-7091-6475-4_7

  4. Tavakkoli F. Proceedings of the 18th expert committee on the selection and use of essential medicines; 2011 March 21-25; Baltimore, Maryland. USA.

  5. Michinaga S, Koyama Y. Pathogenesis of brain edema and investigation into anti-edema drugs. Int J Mol Sci. 2015;16(5):9949–75. https://doi.org/10.3390/ijms16059949

  6. Shawkat H, Westwood MM, Mortimer A. Mannitol: a review of its clinical uses. Contin Educ Anaesth Crit Care Pain. 2012;12(2):82–5. https://doi.org/10.1093/bjaceaccp/mkr063

  7. Mohanty S, Mishra SK, Patnaik R, Dutt AK, Pradhan S, Das B, et al. Brain swelling and mannitol therapy in adult cerebral malaria: a randomized trial. Clin Infect Dis. 2011;53(4):349–55. https://doi.org/10.1093/cid/cir405

  8. Jha SK. Cerebral edema and its management. Med J Armed Forces India. 2003;59(4):326–31. https://doi.org/10.1016/S0377-1237(03)80147-8

  9. Wani AA, Ramzan AU, Nizami F, Malik NK, Kirmani AR, Bhatt AR, et al. Controversy in use of mannitol in head injury. Indian J Neurotrauma. 2008;5(1):11–3. https://doi.org/10.1016/S0973-0508(08)80022-6

  10. Cruz J, Minoja G, Okuchi K, Facco E. Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial. J Neurosurg. 2004;100(3):376–83. https://doi.org/10.3171/jns.2004.100.3.0376

  11. Li J, Wang B. Hyperosmolar therapy for the intracranial pressure in neurological practice: mannitol versus hypertonic saline. IJAR. 2013;1:56–61. https://doi.org/10.1097/MCC.0b013e32835eba30

  12. Marcin JP, Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, et al. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr. 2002;141(6):793–7. https://doi.org/10.1067/mpd.2002.128888

Published
2018-12-31
How to Cite
1.
Sekarningrum PA, Wati DK, Suwarba IM, Hartawan INB, Mahalini DS, Suparyatha IG. Early mannitol administration improves clinical outcomes of pediatric patients with brain edema. Med J Indones [Internet]. 2018Dec.31 [cited 2024Apr.19];27(4):244-9. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/2377
Section
Clinical Research